NCT01059305View on ClinicalTrials.gov

Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Skin Cancer
Interventions
DRUG

Erlotinib

150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

OSI Pharmaceuticals
All Listed Sponsors
collaborator

OSI Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER